FOLD实时信号 | 通过Getagraph.com最大化利润

购买 107717 min ago

@ $13.20

发出时间: 15 Feb 2024 @ 04:36

回报率: -21.02%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: 1.62 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 23:53):

Stats
今日成交量	259 255
平均成交量	3.06M
市值	3.09B
EPS	$0 ( 2024-02-28 )
下一个收益日期	( $-0.0600 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-20.44
ATR14	$0.00800 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Prout Samantha	Sell	7 027	Common Stock
2024-04-01	Campbell Bradley L	Buy	7 500	Common Stock
2024-04-01	Campbell Bradley L	Sell	7 500	Common Stock
2024-04-01	Campbell Bradley L	Sell	7 500	Stock Options (right to buy)
2024-03-15	Campbell Bradley L	Sell	13 375	Common Stock

INSIDER POWER
17.39
Last 100 transactions
Buy: 1 738 926 \| Sell: 1 191 633

音量相关性

長: 0.13 (neutral)

短: 0.45 (neutral)

Signal:(67.321) Neutral

Amicus Therapeutics Inc 相关性

10 最正相关
FULC	0.898
SMSI	0.893
SLS	0.878
PRAX	0.86
GRFS	0.851
CNDT	0.851
NVCR	0.849
LPCN	0.848
SYBX	0.848
ICCC	0.846

10 最负相关
TLMD	-0.848
CNCE	-0.828
TYHT	-0.812
OPCH	-0.811
EPZM	-0.809

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Amicus Therapeutics Inc 相关性 - 货币/商品

0.04
( neutral )

0.11
( neutral )

0.00
( neutral )

0.75
( moderate )

-0.20
( neutral )

Amicus Therapeutics Inc 财务报表

Annual	2023
营收:	$399.36M
毛利润:	$354.16M (88.68 %)
EPS:	$-0.510

FY	2023
营收:	$399.36M
毛利润:	$354.16M (88.68 %)
EPS:	$-0.510

FY	2022
营收:	$329.23M
毛利润:	$290.63M (88.28 %)
EPS:	$-0.820

FY	2021
营收:	$305.51M
毛利润:	$271.05M (88.72 %)
EPS:	$-0.920

Financial Reports:

No articles found.

Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.